Advanced NanoTherapies

Focus: Advanced NanoTherapies develops nanoparticle-enabled medical devices that improve drug uptake and cellular retention, currently focused on cardiovascular applications. The company operates as a pre-revenue or early-stage medical device innovator with limited public financial disclosure.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Advanced NanoTherapies

AI assessmentNot Hiring

No open roles listed right now. Follow Advanced NanoTherapies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Dual-API Coated PTCA Balloon Catheter

Coronary Artery Disease

N/A

Clinical Trials (1)

NCT05521542Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease

N/A

Help build intelligence for Advanced NanoTherapies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep expertise in nanoparticle technology and drug delivery—a differentiated platform with broad therapeutic potential beyond current cardiovascular focus.
Early-stage opportunity to shape a novel medical device category with only 2 active clinical trials, meaning substantial growth runway.
Platform approach reduces single-asset risk; validated science in dual-API coated balloon catheter demonstrates translational viability.

Watch Out For

Zero active job openings and sparse public headcount data suggest minimal hiring or possible dormancy—difficult to assess hiring velocity or team strength.
No published financial data, revenue, or R&D spend disclosed; extremely limited public visibility into funding, burn rate, or commercial traction.
Only 2 trials active and no marketed products; no near-term catalysts, revenue inflection, or clinical milestone visibility to de-risk career stability.

Generated by Claude from Advanced NanoTherapies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter

Angina (Stable)

N/A

Clinical Trials (1)

NCT07368933Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

2 pipeline

Marketed

Pipeline